Clincosm LogoSign in Get a demo

Progression of Hematopoietic Diseases in Shanghai, China

Sponsor
University of Colorado, Denver (Other)
Overall Status
Completed
CT.gov ID
NCT00365014
Collaborator
Fudan University (Other), University of Cincinnati (Other), ExxonMobil Biomedical Sciences, Inc. (Industry), British Petroleum P.L.C. (Industry), Chevron Corporation (Industry), ConocoPhillips (Industry), Exxon Mobil (Industry), Marathon Ashland (Other), Shell Chemicals (Industry)
10,757
Enrollment
1
Location
76
Duration (Months)
141.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    10757 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.
    Study Start Date :
    Aug 1, 2003
    Actual Primary Completion Date :
    Dec 1, 2009
    Actual Study Completion Date :
    Dec 1, 2009

    Arms and Interventions

    Arm Intervention/Treatment
    Blood disease patients

    People with blood diseases presenting at Shanghai hospitals

    Outcome Measures

    Primary Outcome Measures

    1. blood diseases presenting at Shanghai hospitals [hospital stay]

      characterization of people with blood diseases presenting at Shanghai hospitals

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Men and women 18 years or older Diagnosis of hematologic abnormality

    Exclusion Criteria:

    Children Non hematologic diseases

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Joint Sino-US Clinical and Molecular Laboratory (JCML) Shanghai China 200032

    Sponsors and Collaborators

    • University of Colorado, Denver
    • Fudan University
    • University of Cincinnati
    • ExxonMobil Biomedical Sciences, Inc.
    • British Petroleum P.L.C.
    • Chevron Corporation
    • ConocoPhillips
    • Exxon Mobil
    • Marathon Ashland
    • Shell Chemicals

    Investigators

    • Principal Investigator: Richard D Irons, PhD, University of Colorado at Denver and Health Sciences Ctr.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT00365014
    Other Study ID Numbers:
    • 02-0036
    First Posted:
    Aug 16, 2006
    Last Update Posted:
    Jul 23, 2013
    Last Verified:
    Jul 1, 2013
    Keywords provided by University of Colorado, Denver
    aplastic anemia
    myelodysplastic syndromes
    cytopenias
    acute myeloid leukemia
    myelodysplastic/myeloproliferative diseases
    benzene poisoning
    Additional relevant MeSH terms:
    Hematologic Diseases

    Study Results

    No Results Posted as of Jul 23, 2013